Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | Amyloid beta |
Clinical data | |
Trade names | Leqembi |
Other names | BAN2401, lecanemab-irmb |
AHFS/Drugs.com | Monograph |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6544H10088N1744O2032S46 |
Molar mass | 147181.62 g·mol−1 |
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease.[3][4] Lecanemab is an amyloid beta-directed antibody.[3] It is given via intravenous infusion to patients with mild cognitive impairment or mild dementia.[3] In clinical trials, it demonstrated modest efficacy in reducing relative cognitive decline compared to placebo.[5] The most common side effects of lecanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities, a side effect known to occur with the class of antibodies targeting amyloid.[6]
Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States in January 2023,[7] and fully approved by the FDA in July 2023.[4][8] Lecanemab was priced at $26,500 per year in the United States.[9] The European Medicines Agency ruled against approving the drug.[10] In Great Britain, the drug was approved but will not be covered by the English NHS due to its unfavorable benefit–cost ratio.
FDA PR 20230706
was invoked but never defined (see the help page).